Board of directors

The Board of directors is a unique combination of medical, epidemiological and statistical expertise, combined with international business development and innovation experience. The team has more than 250 publications in international peer-reviewed journals and several team members have ongoing research activities in relevant areas of pharmacoepidemiology, cancer epidemiology, cancer modelling, cancer genomics and advanced biostatistics and machine learning.

Ketil Widerberg, Chairman of the board

Ketil Widerberg leads Oslo Cancer Cluster, a cancer innovation member organization, and OCC Incubator, a leading European life science incubator. Previously Ketil has over a decade of experience in biotech and software business development. He holds an MBA from the University of Cambridge and was a member of the NHO forum for health and industry 2017 and a member of the health data expert committee from the Ministry of health 2017.

Arnoldo Frigessi di Rattalma, Board Member

Professor at the Department of Biostatistics and director of the Oslo Centre for Biostatistics and Epidemiology (OCBE) with the Institute of Basic Medical Research at the University of Oslo and the Oslo University Hospital. Frigessi leads the centre for research based innovation BigInsight. His research has focused on Bayesian statistics, on both the methodological and applied side. He has supervised more than 40 PhD students, published more than 150 peer reviewed papers and is a elected member of the Norwegian Academy of Science and Letters.

Lena Nymo Helli, Board Member

Lena is a pharmacist with more than 25 years experience from international pharmaceutical industry. She is currently CEO of Norway Health Tech, and has worked in many phases of the product life cycle from R&D to sales and marketing. She has had roles as medical director, commercial director and also recently General Manager in Norway. Lena holds a Master of Science in Pharmacy from the University of Oslo, Norway and Christian-Albrechts University in Kiel, Germany, as well as Business Economy from the Norwegian Business School (BI).

Steinar Thoresen, Board Member

Steinar Thoresen is a trained pathologist with a PhD on breast cancer and long-time experience in cancer epidemiology. He worked for more than 20 years at The Cancer Registry of Norway, also as Director for The National Cancer Screening-Program. At the same time he did diagnostic pathology in the period 1985-2006. He has published more than 100 international papers on cancer-epidemiology and was associated professor at The University of Bergen for 15 years (Cancer Pathology). Steinar spent one year at Harvard Medical School and worked at Dana Farber Cancer Institute in Boston. Steinar has also extensive experience from the pharma-industry since 2006, being Medical Director both in Abbvie and GSK. Since 2019 he has been Strategy Director for The Nordics and The Baltics for Merck AB.

Christian Jonasson, Board Member

Christian brings over 25 years of diverse experience from R&D roles in pharma, in academia and from the governmental sector. For over a decade, his sole focus has been on epidemiology and health data, also being the Chief Scientific Officer in a Norwegian biobank company. Christian has extensive knowledge and insight of the Nordic health data and biobank research infrastructures. He is a co-affiliated Senior Researcher at the Norwegian University of Science and Technology (NTNU) with active research in the field of pharmaco- and molecular epidemiology. Christian join NordicRWE from the position as Specialist Director Health Data at the Norwegian Institute of Public Health. Christian holds a Master of Science in Pharmacy from Uppsala University and a Ph.D. from the University of Bergen.